Speculation surged across the tape as traders piled into a company reinventing itself around decentralized AI, with the name change and digital asset focus driving outsized momentum.
Confidence also rippled through biotech after a deep-pocketed investor disclosed a major ownership stake. However, health insurers tumbled after a surprise policy proposal threatened future Medicare reimbursement growth.
Gold Surge (Sponsored)
Many investment banks just raised their targets to $6,000/oz... mere weeks after predicting $5,000. Even Jim Cramer now admits to being a "gold bug."
But nearly everyone is missing an even bigger story: the absolute best way to invest in gold right now.
Markets
Wall Street was undecided as tech gains driven by chip strength and earnings optimism lifted the Nasdaq and S&P 500, while healthcare and industrial weakness, led by insurers and Boeing, dragged down the Dow ahead of the Fed decision.
DJIA [-0.83%]
S&P 500 [+0.41%]
Nasdaq [+0.91%]
Russell 2k [+0.23%]
Market-Moving News
Retail Strategy
Amazon Finally Chooses a Grocery Winner
Amazon (NASDAQ: AMZN) is ending years of grocery experimentation and betting hard on what customers already use. Fast online delivery is now the growth engine, not futuristic stores that look good in demos but stall at scale.
Same-Day grocery delivery now reaches thousands of U.S. cities and towns. When food lands in the same cart as detergent and paper towels, you are reinforcing a habit, not chasing novelty.
Whole Foods Gets the Keys
Whole Foods Market is no longer just a premium side brand; it is Amazon’s physical grocery backbone. Plans for more than 100 new stores show confidence in demand, margins, and brand trust.
Smaller Daily Shop locations push Whole Foods closer to everyday convenience. You are seeing Amazon lean into frequency instead of foot traffic experiments.
Goodbye Cool Stores, Hello Clean Economics
Amazon Go and Amazon Fresh physical stores are being shut down because they never found economic escape velocity. The formats taught lessons, but lessons do not justify permanent capital burn.
Checkout tech and operational insights are being kept and redeployed elsewhere. Amazon is cutting the wrapper while keeping the intelligence.
This Is Amazon Choosing Discipline
This reset simplifies Amazon’s grocery playbook into something brutally clear. Delivery drives growth, Whole Foods anchors retail, and everything else gets trimmed.
You are watching Amazon move from curiosity to conviction. In groceries, boring that works beats clever that doesn’t, and Amazon has picked its side.
Health
Intellia Gets Back in the Game, and the Stakes Are Real
After months in regulatory limbo, Intellia Therapeutics (NASDAQ: NTLA) has been cleared to restart patient enrollment in its late-stage gene-editing trial. That decision restores momentum to a program that was quietly carrying the company’s long-term credibility.
When regulators step in this late, it forces hard questions about safety and platform risk. Getting the green light back does not erase those concerns, but it keeps the story alive.
Why This One Program Carries So Much Weight
This therapy is not just another asset; it is the centerpiece of Intellia’s in vivo CRISPR ambition. A successful outcome would show that one-time gene editing can move beyond theory and into durable, real-world treatment.
You are not looking at a maintenance drug or recurring revenue model. This is a bet on permanence, where clinical success reshapes how disease control is defined.
Regulatory Confidence Is a Platform Asset
The restart signals that Intellia addressed safety questions through tighter monitoring and protocol changes. That matters because regulators tend to judge platforms, not just individual trials.
Once trust erodes, every program pays the price. This clearance helps stabilize perception across Intellia’s broader pipeline.
The Risks Did Not Leave the Room
A related cardiac study remains on hold, reminding everyone that scrutiny is still intense. Any new safety signal could slow progress again without warning.
For now, Intellia has breathing room, not victory. You are watching a company get a second chance to prove that gene editing can deliver medicine, not just headlines.
Here’s How (Sponsored)
Most investors assume pre-IPO opportunities are only for insiders.
But according to James Altucher, there’s a simple workaround that may allow everyday investors to gain early exposure to SpaceX—starting with just $100.
It doesn’t require special permissions or private deals.
Instead, James walks through:
The exact asset he’s using
How it fits inside a normal brokerage account
Why this approach could benefit if SpaceX goes public
He explains everything in a short, free video—so you can evaluate it yourself.
Watch the explanation here
Advisory Services
Why WTW’s Newfront Deal Hits Different
WTW (NASDAQ: WTW) completed its acquisition of Newfront to take ownership of how insurance advice is delivered, priced, and executed in the U.S. middle market. The goal is not scale for its own sake, but control over workflows that increasingly define client experience.
Newfront brings automation, real-time analytics, and software-native client tools into a business still dominated by manual processes. When you strip away the press language, this is WTW choosing infrastructure over incremental growth.
Fast-Growth Clients Broke the Old Model
High-growth companies do not want insurance to feel like an annual negotiation. They want visibility, flexibility, and speed that match how they run finance and operations.
WTW is using Newfront to meet that expectation without rebuilding from scratch. When you think about where fintech, life sciences, and tech clients are heading, this move closes a widening gap.
This Only Works If Execution Does Not Blink
Integrating technology platforms, retaining producers, and aligning culture will determine whether this becomes a true advantage. Insurance is unforgiving when transitions break trust or slow response times.
WTW is betting that owning modern rails beats renting them. That bet matters because you do not get a second chance to modernize while competitors are already moving.
Want to make sure you never miss our post-market roundup?
Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone right after the closing bell rings.
Email’s great. Texts are faster.
Top Winners and Losers
Flora Growth Corp [FLGC] $11.00 (+74.05%)
Flora Growth surged after announcing a rebrand to ZeroStack and a strategic shift toward decentralized AI investments, including a large position in the 0G token ecosystem.
Biomx Ltd [PHGE] $6.77 (+65.12%)
BiomX soared after an investor disclosed a nearly 20% ownership stake, signaling strong external confidence in the company’s future prospects.
Richtech Robotics Inc [RR] 5.51 (+44.62%)
Richtech Robotics climbed after announcing a collaboration with Microsoft’s AI Co-Innovation Labs to deploy advanced agentic AI capabilities in real-world robotic systems.
Commvault Systems [CVLT] $88.63 (-31.49%)
Commvault slipped despite beating earnings as investors focused on softer forward growth expectations and a sharp drop in free cash flow, signaling moderating momentum ahead.
Sanmina Corp [SANM] $143.18 (-21.56%)
Sanmina declined as investors reacted to weaker-than-expected forward revenue guidance and margin pressure, which dampened enthusiasm around its strong quarterly sales growth.
Humana Inc [HUM] $208.00 (-21.10%)
Humana and other health insurers plunged after regulators proposed a near-flat Medicare Advantage payment rate increase, threatening future margins across the sector.
Poll: You have to choose one metric to track weekly—what’s most useful?
Hold Forever (Sponsored)
A new set of 7 AI stocks are DOMINATING the market.
Here’s why one financial guru says they could be the most famous companies in the world by 2030.
Everything Else
Boeing swung back to a quarterly profit on asset sales, though lingering unit losses kept the turnaround story from feeling clean.
A tech-led push carried the S&P 500 to a fresh record, with momentum doing most of the talking.
UnitedHealth is forecasting its first revenue decline in nearly 40 years, a rare stumble for a company built on steady growth.
General Motors saw core profit climb as demand held firm for SUVs and pickup trucks, underscoring where its pricing power still lives.
U.S. banks could see as much as $500 billion drift toward stablecoins by 2028, a slow leak that starts looking like a real threat once it adds up.
That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!
Thanks for reading. I'll see you at the next open!
Best Regards,
— Adam G.
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
